You just read:

EuroPCR Late-Breaking Clinical Trials: MiStent SES® Shows Clinical Superiority over Market-Leader Xience V in Propensity Analysis at One and Three Years Post-Treatment

News provided by

Micell Technologies

19 May, 2015, 13:00 BST